RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.1
RINVOQ could give your patients itch relief they can feel & skin clearance you can see1
as many patients on RINVOQ simultaneously achieving little to no itch (WP-NRS 0-1) and almost clear skin (EASI 90) at Week 162-4
as many patients achieving little to no itch (WP-NRS 0-1) as early as Week 4 and ≈2× through Week 162,4
as many patients achieving almost clear skin (EASI 90) as early as Week 4 and ≈2× through Week 162,3
Superior itch reduction (WP-NRS†) and superior skin clearance
(EASI 75) at Week 16 with RINVOQ 30 mg5
FOR DUPI-IR†† PATIENTS, A SWITCH TO RINVOQ HELPED PATIENTS ACHIEVE LITTLE TO NO ITCH AND ALMOST CLEAR SKIN‡‡
AT WEEK 3215,§
Minimal disease activity (WP-NRS 0-1 and EASI 90) achievement over 2.5 years6,7,‡,§,†††
Rapid improvements in head, neck, and hand eczema with improvements in patients’ QoL at Week 168-10,*,‡,§
Over 2.5 years of improvement in sleep disturbance (ADerm-IS Sleep score of 0-1) and DLQI 0-111,‡,§
6 years of consistent AD safety data, including in patients as young as 12 years of age12,ǁ
patients with moderate to severe AD on RINVOQ globally13
patients on RINVOQ worldwide across 7 indications13,¶
Well-established safety profile across 10 years** of research and >20 clinical trials in 8 indications1,2,5,14
§§ELEVATE: AbbVie defines "ELEVATE" as the raising of the standards of care in AD patients, measured by WP-NRS and EASI score, treated with Dupilumab vs RINVOQ at week 16 of the head to head trials.2,5 ‖CHALLENGE EXPECTATIONS: AbbVie defines "CHALLENGE EXPECTATIONS" as the raising of standards of care in AD patients, measured by WP-NRS and EASI score, treated with Dupilumab vs RINVOQ at week 16 of the head to head trials.2,5 *LEVEL UP (RINVOQ initiated at 15 mg QD vs dupilumab administered per its label) and HEADS UP (RINVOQ 30 mg QD vs dupilumab 300 mg SC Q2W) were 2 H2H studies powered to evaluate the superiority of RINVOQ vs dupilumab in AD. LEVEL UP: The primary endpoint (WP-NRS 0-1 + EASI 90 at Week 16) and all ranked secondary endpoints were met (P<0.001 RINVOQ vs dupilumab). HEADS UP: The primary endpoint (EASI 75 at Week 16) and all ranked secondary endpoints were met (P=0.007 and P<0.001 RINVOQ 30 mg vs dupilumab, respectively). Achievement of head and neck EASI 90/100 was assessed in a post hoc analysis.2,5,8 †Mean percentage change in WP-NRS from baseline.5 ‡MEASURE UP 1 & 2: The coprimary endpoints (EASI-75 and vIGA-AD 0/1 at Week 16) and all ranked secondary endpoints were met in both studies (P<0.0001 RINVOQ vs placebo). Achievement of minimal disease activity (WP-NRS 0-1 + EASI 90 through Week 140), HECSI 75, and head and neck EASI <1 were assessed in post hoc analyses.7,9-11,16 §Data were nonranked endpoints not controlled for multiplicity. Thus, results cannot be considered statistically significant.7-11,15 ǁThe recommended dose of RINVOQ is 15 mg QD for adolescents (12-17 years of age) weighing at least 30 kg. If an adolescent patient does not respond adequately to RINVOQ 15 mg once daily, the dose can be increased to 30 mg once daily. The posology in adolescent patients 30 kg to <40 kg was determined using population pharmacokinetic modeling and simulation. No clinical exposure data are available in adolescents <40 kg. The safety and efficacy of RINVOQ in children with AD below the age of 12 years have not been established. No data are available.1 ¶183,634 patients with RA, 67,914 patients with SpA (PsA, AS & nr-axSpA), 109,946 patients with AD, 54,780 patients with UC and 43,308 patients with CD.13 **Across RA, PsA, AS, nr-axSpA, GCA, AD, UC, and CD.1,2,5,14 ††DUPI-IR is defined as <EASI 75 response at Week 16.15 ‡‡WP-NRS 0-1 and EASI 90 at Week 32, among patients who did not simultaneously achieve WP-NRS 0-1 and EASI 90 at Week 16.15 †††The achievement of WP-NRS 0-1 and EASI 90 is an example of minimal disease activity, defined as the simultaneous achievement of optimal treatment targets17
FIND OUT MORE ABOUT RINVOQ
REFERENCES
- RINVOQ® (upadacitinib) Summary of Product Characteristics, available at www.medicines.ie.
- Silverberg JI, Bunick CG, Hong HC, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up). Br J Dermatol. 2024;192(1):36-45.
- Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353-1357.
- Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502-507.
- Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047-1055.
- Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(11):2139-2148.
- Prajapati VH, Bunick CG, Eyerich K, et al. Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate to severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies. Presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) Conference, June 8-10, 2024, Chicago, IL, USA.
- Thyssen JP, Rosmarin D, Costanzo A, et al. Efficacy and safety of upadacitinib versus dupilumab treatment for moderate-to-severe atopic dermatitis in four body regions: analysis from the Heads Up study. Dermatology. 2025;241(1):10-18.
- Eyerich K, Mendes-Bastos P, Holzer G, et al. Efficacy of upadacitinib in treating atopic dermatitis in the head and neck regions. Presented at European Academy of Dermatology and Venerology (EADV); Sept 25-28, 2025, Amsterdam, The Netherlands.
- Simpson EL, Rahawi K, Hu X, et al. Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials. J Eur Acad Dermatol Venereol. 2023;37(9):1863-1870.
- Simpson EL, Aoki V, Golant AK, et al. Sustained Improvement in Patient-Reported Sleep, Daily Activity, and Emotional State With Long-Term Upadacitinib Treatment: 140-Week Atopic Dermatitis Impact Scale (ADerm-IS) Results From Phase 3 Measure Up 1 and Measure Up 2 Studies. Presented at the 2024 European Academy of Dermatology & Venereology Congress, 25-28 September 2024, Amsterdam, Netherlands [Ref DV# 012605].
- Bunick C, Silverberg SI, Chovatiya R, et al. Long-Term Upadacitinib Safety in Moderate to Severe Atopic Dermatitis up to 6 Years: An Integrated Analysis With Over 9000 Patient Years of Exposure. Presented at the 2024 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, December 8, 2024 [Ref DV# 013407].
- AbbVie. Data on File. ABVRRTI80819.
- Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503-2512.
- Bunick CG, Magnolo N, Moore A, et al. Switching from dupilumab to upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study. Presented at Fall Clinical Dermatology Conference, Las Vegas, NV, October 24-27, 2024.
- Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151-2168.
- Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consen- sus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(11):2139-2148.
IE-RNQD-260008 Date of Preparation: May 2026
